Ipamorelin vs Tesamorelin: A Ghrelin-Mimetic Pentapeptide and a GHRH Analog Compared

Published September 2026 · Patriot Labs Research Team · ~18 min read

The short answer

Ipamorelin and tesamorelin are both growth-hormone secretagogues, but they sit at opposite ends of the class: ipamorelin is a five-residue synthetic peptide that mimics ghrelin and binds the ghrelin receptor (GHS-R1a), while tesamorelin is a full 44-residue analog of growth-hormone-releasing hormone (GHRH) that binds the separate GHRH receptor. They act on the same pituitary cell, but through different receptors, different signalling pathways and on wildly different molecular scales.

Everything else follows from that split. Because they bind different receptors, they trip different internal machinery. Because one is a tiny engineered fragment and the other a full-length hormone analog, they are stabilized by completely different chemistry and behave differently in a vial. And because tesamorelin became an approved drug while ipamorelin never did, the two carry very different regulatory and evidence histories. The sections below take each of those contrasts in turn. For the individual molecules in more depth than a side-by-side allows, the site’s explainers on Ipamorelin and Tesamorelin are the natural companions to this page, and the closely related CJC-1295 vs Ipamorelin comparison covers the same ghrelin-versus-GHRH divide from the other side.

What each molecule actually is

The two structures answer the comparison before any pharmacology is discussed: they are not the same kind of molecule, and the mismatch in size is the first thing to notice.

Ipamorelin is a pentapeptide — five residues — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂, where Aib is the non-natural amino acid aminoisobutyric acid and D-2-Nal is a D-form naphthylalanine.¹ Its molecular formula is C₃₈H₄₉N₉O₅ and its molecular weight is about 711.9 daltons (CAS 170851-70-4).² The C-terminus is amidated, and the deliberate inclusion of D-form and non-natural residues is the whole design point: they make a five-residue chain far harder for ordinary peptidases to cleave than five standard L-amino acids would be.

Tesamorelin is a different order of object. It reproduces the complete 44-amino-acid sequence of human GHRH — the native hypothalamic hormone in full, not a fragment — and adds a trans-3-hexenoic acid group to the N-terminus.³ Its molecular formula is reported as C₂₂₁H₃₆₆N₇₂O₆₇S with a molecular weight near 5,135.9 daltons (CAS 218949-48-5).⁴ That single sulphur atom in the formula (the S) is a reminder that, unlike the little pentapeptide, tesamorelin carries the full complement of a natural hormone’s residues, including a methionine. So one compound is a compact, rugged five-mer and the other a full-length hormone analog with a lipophilic cap — a roughly seven-fold difference in mass that governs almost everything downstream, from receptor choice to how a laboratory weighs and identifies each one.

Two receptors on the same cell

This is the core of the comparison. The two peptides bind different receptors, and that single fact explains why they are complementary rather than interchangeable. Growth-hormone release from the pituitary is governed by a push-and-pull system: GHRH stimulates release, somatostatin inhibits it, and ghrelin acts as a third input that both stimulates release and blunts the inhibitory brake. Ipamorelin and tesamorelin plug into two different parts of that system.

Tesamorelin, the GHRH analog, binds the GHRH receptor on the somatotroph — the same receptor the native hypothalamic hormone uses. That receptor is a class-B G-protein-coupled receptor that couples to the G_s protein, activating adenylyl cyclase, raising intracellular cyclic AMP (cAMP) and switching on protein kinase A. In research models this pathway drives the synthesis of growth hormone and increases the amplitude of the pulses the cell releases. Because tesamorelin is the full-length hormone rather than a fragment, it engages that receptor as the natural ligand does.

Ipamorelin, the ghrelin mimetic, binds the ghrelin receptor (GHS-R1a) — the receptor first cloned in 1996 and described as a “growth hormone secretagogue receptor” before its natural ligand ghrelin had even been identified.⁵ Ghrelin itself, the stomach-derived acylated peptide that turned out to be that ligand, was reported in 1999.⁶ GHS-R1a couples to a different G protein, G_q/11, activating phospholipase C and raising intracellular calcium through the IP₃ pathway. In the intact animal this arm does something the GHRH arm cannot: it helps oppose somatostatin, the inhibitory signal, and helps initiate a growth-hormone pulse. So where the GHRH signal sets the size of the release, the ghrelin-receptor signal helps trigger it and lifts a brake on it. Two receptors, two G proteins, two second messengers — cAMP on the tesamorelin side, calcium on the ipamorelin side — converging on one cell.

The selectivity of ipamorelin is worth stating precisely, because it is the fact that made the compound durable as a research tool. When it was characterized in 1998, investigators reported that it released growth hormone with a selectivity resembling GHRH itself: it did not meaningfully raise ACTH or cortisol even at doses far above those needed for its growth-hormone effect, and it left prolactin, FSH, LH and TSH essentially untouched.¹ Earlier peptides in the same GHRP family, such as GHRP-6 and GHRP-2, did nudge those other outputs upward.

Two different solutions to the same enzyme problem

Both molecules face the same threat — peptidases that would clip a naked peptide apart in minutes — and both are engineered against it, but by opposite strategies that follow from their sizes. The general toolkit for making peptides last is covered in the companion guide on peptide half-life extension; ipamorelin and tesamorelin are a clean illustration of two of its approaches.

Ipamorelin protects itself by composition. Rather than add anything to a normal peptide, it is built from residues enzymes struggle to recognize: the non-natural Aib at the N-terminus and the D-form 2-naphthylalanine and D-phenylalanine in the middle. D-amino acids are the mirror image of the L-amino acids that peptidases evolved to cut, so a chain containing them resists cleavage without any external modification. That built-in ruggedness, combined with its small size, gives ipamorelin a reported laboratory half-life on the order of two hours.²

Tesamorelin protects itself by capping. It keeps the full native GHRH sequence — which on its own is fragile — and bolts a trans-3-hexenoic acid group onto the N-terminus. Native GHRH is clipped almost immediately by the enzyme dipeptidyl peptidase-4 (DPP-4), which attacks the front of the chain; the lipophilic hexenoyl cap blocks that access and makes the analog markedly more resistant to that cleavage than the unmodified hormone.³ Even so, tesamorelin’s reported circulating half-life is short — roughly 26 to 38 minutes in the approved-drug pharmacology³ — because a large peptide is still cleared quickly by other routes. The contrast is instructive: the small peptide outlasts the large one, precisely because its protection is woven through every residue rather than concentrated at one end.

Different labs, different decades, different fates

The two molecules also come from different corners of pharmaceutical history, and their regulatory fates diverged completely. Ipamorelin was developed in the late 1990s by researchers at Novo Nordisk (it carries the internal code NNC 26-0161) and reported in a 1998 paper in the European Journal of Endocrinology titled, plainly, “Ipamorelin, the first selective growth hormone secretagogue.”¹ Despite a clean preclinical profile and continued use as a reference agonist, it never advanced to an approved indication; it remains a research compound with no brand name and no marketing authorization anywhere.

Tesamorelin followed the opposite path. Developed by the Canadian company Theratechnologies (originally coded TH9507), it went through randomized controlled trials and, in November 2010, was approved by the US FDA under the brand name Egrifta for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy — the first and, for years, only drug approved for that use.⁷ That distinction matters for anyone comparing the two: one of these names belongs to an approved medicine with a defined label and a regulated manufacturing standard, and the other does not. As always, a research compound that shares a name with an approved drug is not that drug; the difference between research-grade material and pharmaceutical product is the subject of the site’s guide on peptide versus drug versus biologic.

Side by side

The contrasts are easiest to read in a single view. The table below sets the two molecules against each other on the properties that actually distinguish them.

The research record

The two peptides also differ sharply in how deep and what kind of published record stands behind each name.

Ipamorelin’s record is largely preclinical. The foundational 1998 paper established its selectivity in animal and cell models,¹ and subsequent work extended into skeletal endpoints: a 1999 study reported that ipamorelin induced longitudinal bone growth in rats,⁸ and a 2000 study in the Journal of Endocrinology found that ipamorelin and GHRP-6 increased bone mineral content in adult female rats.⁹ Across the literature ipamorelin recurs as a clean reference agonist for probing GHS-R1a signalling. What it lacks is a body of large randomized human trials, because it was never developed toward approval.

Tesamorelin’s record includes controlled human trials, a direct consequence of its drug-development path. The pivotal report is Falutz and colleagues, 2007, in the New England Journal of Medicine, a randomized, double-blind, placebo-controlled study of tesamorelin in HIV-infected patients with excess abdominal fat.¹⁰ Later analyses examined durability and metabolic endpoints, including a 2010 report in the Journal of Acquired Immune Deficiency Syndromes¹¹ and a 2012 study associating reduced visceral fat with an improved metabolic profile.¹² A 2014 randomized trial in JAMA further examined tesamorelin’s effect on visceral and liver fat.¹³ These studies concern the approved drug in its studied population and are cited here to describe the evidence base, not to imply anything about a research compound or any use outside those trials.

Why the two pathways are studied together

Because ipamorelin and tesamorelin engage the two distinct natural inputs to the somatotroph, the pairing of a GHRH-receptor agonist with a ghrelin-receptor agonist is a recurring research paradigm. The logic is the same one behind the widely studied CJC-1295-plus-ipamorelin combination, in which a GHRH analog and a ghrelin mimetic are examined together: the two receptors sit on the same cell, use different G proteins, and in the intact system the ghrelin arm also counteracts somatostatin. Investigators combine agonists of both arms to ask whether dual-pathway stimulation of the growth-hormone axis behaves differently from either input on its own. Tesamorelin occupies the GHRH-receptor role in that framework, exactly as CJC-1295 does; ipamorelin is the ghrelin-receptor half in both pairings. The reason the axis is so often studied through blends of complementary signals is explored in the guide on why peptides are studied in blends.

Bench practice: characterizing a small peptide and a large one

The size gap between the two is not just a curiosity; it changes how a laboratory identifies and checks each compound. On mass spectrometry, ipamorelin’s roughly 712-dalton mass sits in a range where a single-charge signal is straightforward to read, while tesamorelin’s ~5,136-dalton mass typically appears as a series of multiply-charged states that must be deconvoluted to confirm identity. On reversed-phase HPLC, a five-residue peptide and a 44-residue one behave very differently, and the acceptance criteria that define purity are set per compound. Neither is inherently harder to make well; each simply requires its own reference method. The general principles of what an identity-and-purity workup proves — and what a certificate of analysis can and cannot show — are covered in understanding peptide COA testing. Patriot Labs tests every batch of both peptides by HPLC for purity and by mass spectrometry for identity at an independent US laboratory, with the certificate of analysis published on each product page.

What the evidence does not establish

This guide compares two molecules on chemistry, mechanism and published research. Several things it deliberately does not do:

• It does not describe or compare effects in humans or animals. Mechanisms are described as studied in research systems; nothing here states what either compound does in a person, and no use in a person or animal is described or implied.
• It does not rank the two or suggest one is preferable. They act through different receptors and carry different evidence bases; a comparison of properties is not a judgement of merit for any purpose.
• It draws no equivalence between the research compound and the approved drug. Tesamorelin’s approval and trials concern the pharmaceutical product Egrifta in its studied population. A research-grade compound sharing the name is not that drug and is supplied for laboratory use only.
• Half-life and molecular figures are as reported. Half-lives in particular are model- and context-dependent, and the values cited describe the published literature rather than any fixed constant.
• Nothing here describes how to prepare, dose or administer either compound. The bench section concerns analytical identity and purity only.

Frequently asked questions

What is the difference between ipamorelin and tesamorelin?

They are opposite ends of the growth-hormone secretagogue class. Ipamorelin is a five-residue synthetic peptide that imitates ghrelin and binds the ghrelin receptor (GHS-R1a). Tesamorelin is a full-length 44-residue analog of growth-hormone-releasing hormone (GHRH) that binds the separate GHRH receptor. Both act on the same pituitary cell, but through different receptors, different intracellular pathways and on very different molecular scales.

Are ipamorelin and tesamorelin the same thing?

No. They share only a functional category, growth-hormone secretagogue. Chemically they are unrelated: ipamorelin is a five-amino-acid pentapeptide (about 712 daltons) built with non-natural and D-form residues, while tesamorelin is the entire 44-residue GHRH sequence (about 5,136 daltons) capped with a trans-3-hexenoic acid group. One is roughly seven times the mass of the other.

Do ipamorelin and tesamorelin act on the same receptor?

No. Ipamorelin binds the ghrelin receptor, GHS-R1a, which couples to the G_q/11 protein and raises intracellular calcium. Tesamorelin binds the GHRH receptor, which couples to the G_s protein and raises cyclic AMP. Both receptors sit on the pituitary somatotroph and feed into growth-hormone release, which is why the two compounds are described as acting on the same axis through different doors.

Is tesamorelin FDA approved?

Tesamorelin was approved by the US FDA in November 2010 under the brand name Egrifta, developed by Theratechnologies, for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. That approval applies to the pharmaceutical product made under a regulated quality system. A research-grade compound that shares the name is not the approved drug and is sold for laboratory use only.

Is ipamorelin FDA approved?

No. Ipamorelin has been studied since the late 1990s but has never received FDA approval for any indication and has no approved-drug brand name. It exists only as a research compound. Tesamorelin, by contrast, is an approved drug, which is one of the clearest regulatory differences between the two.

Why are ipamorelin and tesamorelin sometimes studied together?

Because they engage the two natural inputs that drive growth-hormone release from a single cell. Tesamorelin, a GHRH analog, works through the GHRH receptor, while ipamorelin works through the ghrelin receptor and can functionally oppose somatostatin, the inhibitory brake. Researchers combine agonists of these two pathways to study whether dual-receptor stimulation of the somatotropic axis differs from either input alone.

Which is larger, ipamorelin or tesamorelin?

Tesamorelin is far larger. It is a 44-residue peptide with a molecular weight near 5,136 daltons, whereas ipamorelin is a five-residue peptide of about 712 daltons. The size gap governs much of how they behave, including how each is engineered to resist enzymatic breakdown and how a laboratory characterizes them by mass spectrometry.

References

1. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. doi:10.1530/eje.0.1390552; PMID 9849822
2. PubChem. Ipamorelin (Compound Summary): sequence, molecular formula C₃₈H₄₉N₉O₅, molecular weight ~711.9, CAS 170851-70-4, reported half-life. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin
3. Wikipedia contributors. Tesamorelin: GHRH(1-44) analog with trans-3-hexenoic acid N-terminal group, DPP-4 resistance, reported half-life 26–38 minutes. https://en.wikipedia.org/wiki/Tesamorelin
4. PubChem / ChemicalBook. Tesamorelin: molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S, molecular weight ~5,135.9, CAS 218949-48-5. https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
5. Howard, A. D., Feighner, S. D., Cully, D. F., et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974–977. doi:10.1126/science.273.5277.974; PMID 8688086
6. Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656–660. doi:10.1038/45230; PMID 10604470
7. U.S. Food and Drug Administration / Theratechnologies (10 November 2010). FDA approves Egrifta (tesamorelin for injection) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. https://www.drugs.com/history/egrifta.html
8. Johansen, P. B., Nowak, J., Skjaerbaek, C., et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106–113. PMID 10373343
9. Svensson, J., Lall, S., Dickson, S. L., et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology, 165(3), 569–577. https://joe.bioscientifica.com/view/journals/joe/165/3/569.xml
10. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. doi:10.1056/NEJMoa072375
11. Falutz, J., Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. PMID 20101189
12. Stanley, T. L., Falutz, J., Mamputu, J. C., et al. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases, 54(11), 1642–1651. PMID 22495074
13. Stanley, T. L., Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 312(4), 380–389. https://jamanetwork.com/journals/jama/fullarticle/1889139

For the individual compounds and the pathways this comparison touches, see What Is Ipamorelin? and What Is Tesamorelin? for each molecule on its own, CJC-1295 vs Ipamorelin for the closely related GHRH-versus-ghrelin comparison, Peptide Half-Life Extension for the engineering strategies behind both, and Peptide vs Drug vs Biologic for the regulatory categories that separate an approved drug from a research compound.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and compares two research peptides in general scientific terms; it is not medical advice, does not describe how to use any product, and makes no therapeutic claim about either compound.